AUS
NZ
UK
CA
USA
IND
Highlights
Prescient Therapeutics completes Share Purchase Plan to fund PTX-100 development
Launches follow-on placement as part of broader capital strategy
Focus remains on advancing precision oncology and immunotherapy platforms
Prescient Therapeutics Ltd (ASX:PTX), listed on the All Ordinaries, has secured funding through a Share Purchase Plan aimed at accelerating the clinical development of its lead cancer therapy candidate, PTX-100. The company has entered a trading halt to prepare for an additional placement offer following strong demand from sophisticated and professional participants.
The newly secured capital is earmarked for the ongoing Phase 2 clinical trial of PTX-100, supporting its pathway toward regulatory milestones.
PTX-100 Gains Momentum in Global Cancer Trials
PTX-100 is Prescient’s most advanced therapeutic, targeting the enzyme geranylgeranyl transferase-1 (GGT-1), associated with cancer cell growth. The candidate is undergoing Phase 2 trials for Cutaneous T cell lymphoma (CTCL), with international patient enrolment underway.
The program benefits from the Fast Track and Orphan Drug designations granted by the US Food and Drug Administration for treating relapsed or refractory mycosis fungoides, offering a streamlined development route for Prescient.
Strategic Leadership Reinforces Development Pathway
Chief executive officer James McDonnell described the initiative as an inflection point for the business as it aligns toward commercial goals. The raised funds reinforce Prescient’s financial foundation to progress toward those objectives while enabling continued data generation for its clinical programs.
The allotment of shares under the Share Purchase Plan is scheduled in early August, establishing a timeline that aligns with key trial developments.
Broadening Portfolio in Precision Oncology and Immune Therapies
Beyond PTX-100, Prescient continues to expand its pipeline with additional precision oncology assets. These include:
-
CellPryme-M: An immune-boosting adjunct that enhances the tumour-targeting capability and persistence of T-cell therapies.
-
CellPryme-A: Designed to reprogram the tumour microenvironment, supporting enhanced CAR-T cell efficacy.
-
OmniCAR: A modular immune receptor platform allowing customisable, controllable CAR-T therapies across cancer indications.
Prescient’s multi-asset approach places emphasis on novel and flexible platforms that address key limitations in current cancer treatment strategies, aligning with the company’s long-term therapeutic vision.
Prescient is raising capital to support the ongoing clinical development of PTX-100 and accelerate progress toward regulatory milestones.
Which cancer indication is PTX-100 currently being trialled for?PTX-100 is in Phase 2 clinical trials targeting Cutaneous T cell lymphoma (CTCL), with enrolment open globally.
What other treatments are in Prescient’s development pipeline?Prescient's portfolio includes CellPryme-M, CellPryme-A, and OmniCAR — platforms focused on improving immunotherapy outcomes.
